



Fluoxetine, a Selective Serotonin Reuptake Inhibitor Overdose Resulting in a Central Retinal Vein Occlusion

**Satish G. Agraharam¹, Gangaprasad Amula¹, Arjun Srirampur^{1*}
and Aruna Kumari Gadde¹**

¹*Anand Eye Institute, Habsiguda, Hyderabad, Telangana 500007, India.*

Authors' contributions

This work was carried out in collaboration between all authors. Author SGA was the treating clinician in this case. Author GA wrote the protocol. Author AS made corrections and the first draft. Author AKG managed the literature searches. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/OR/2017/35199

Editor(s):

- (1) Li Wang, Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, USA.
(2) John D. Bullock, Wright State University, School of Medicine, USA.

Reviewers:

- (1) Konuralp yakar, Ataturk State Hospital, Sinop Atatürk State Hospital, Turkey.
(2) Alahmady Hamad Alsmman Hassan, Sohag University, Egypt.
(3) Asaad Ahmed Ghanem, Mansoura University, Egypt.
(4) Rodrigo Fabri Berbel, Instituto De Olhos Fabri, Cascavel, Brazil.
Complete Peer review History: <http://www.sciencedomain.org/review-history/20230>

Case Report

Received 30th June 2017
Accepted 25th July 2017
Published 26th July 2017

ABSTRACT

Aim: We present a rare case of Central retinal vein occlusion after prolonged use of Fluoxetine.
Case Presentation: A 28 year old patient presented with clinical picture of Central retinal vein occlusion after prolonged use of Fluoxetine. Discontinuation of the offending drug resulted in resolution of the venous occlusion.
Discussion and Conclusion: Young patient presenting with central retinal vein occlusions require drug history to be elicited to identify the cause.

Keywords: Fluoxetine; selective serotonin reuptake inhibitor; central retinal vein occlusion.

1. INTRODUCTION

Fluoxetine is a selective serotonin reuptake inhibitor which is widely used for the treatment of major depression, obsessive-compulsive disorder (OCD) and panic disorders [1,2]. Their popular use is due to the acceptable side effect profile as well as low morbidity and mortality [3]. Following is an unusual complication of the use of fluoxetine in a patient suffering from OCD.

2. CASE PRESENTATION

A 28 year old gentleman presented to our clinic with a history of decrease in vision in his right eye since 1 month. There was a history of usage of drug fluoxetine (60 mg daily) since 2 months prescribed by his Psychiatrist. There was no other systemic illness or any other relevant medical history. On examination vision was noted to be 6/6; N6 in both eyes. Ocular movements were full, free; there was no presence of relative afferent pupillary defect. Anterior segment examination was unremarkable; intraocular pressures were noted to be 10 mmHg bilaterally. Posterior segment examination of the right eye showed retinal hemorrhages in all quadrants, significant vascular tortuosity and optic disc edema with disc collaterals suggestive of long standing central retinal vein occlusion (CRVO) (Fig. 1). The left eye fundus was normal.



Fig. 1. Right Eye fundus photo showing retinal hemorrhages in all quadrants, significant vascular tortuosity and optic disc edema with disc collaterals suggestive of long standing central retinal vein occlusion

Fluorescein angiography demonstrated delayed venous filling suggestive of venous stasis. There

was no evidence of any vasculitis. In view of the strong suspicion of CRVO post drug usage the patient was asked to stop the drug and asked for follow up. After stopping the drug there was gradual clearing of the retinal hemorrhages and vascular tortuosity. Three months follow up showed normal looking retina with complete clearing of the retinal lesions. At final visit the visual acuity was 6/6 with normal intraocular pressures.

3. DISCUSSION

Central retinal vein occlusion is the second most common retinal vascular disorder after diabetic retinopathy [4,5]. Thrombotic occlusions can occur due to a number of pathogenic insults including vessel compression, vessel wall damage, changes in circulatory dynamics and changes in blood composition and clotting [6].

Selective serotonin reuptake inhibitors (SSRIs) such as Fluoxetine reduce neural serotonin reuptake; they are also known to modulate peripheral serotonin, including that in platelets [7]. Serotonin has been implicated as a potent potentiator in platelet aggregation. In repeated doses, SSRIs have been found to deplete platelet serotonin stores and have therefore been proposed to reduce the risk of hypercoagulability [8]. However, the initial effect of SSRI treatment is to increase serotonin levels within the target tissues, although the duration of this effect is not known [9]. An increase in platelet serotonin secondary to the use of the SSRI fluoxetine has previously been postulated as an etiological factor in the development of deep venous thrombosis [10]. Low mood itself has also been found to increase the risk of thromboembolic stroke through increased platelet activity due to sympatho-adrenal axis hyperactivity.

4. CONCLUSION

In our patient we interpret that the use of fluoxetine was a potentiating factor in the platelet aggregation contributing to his central retinal vein occlusion. To the best of our knowledge this is a rare case of fluoxetine to be reported in the literature to cause a Central retinal vein occlusion. It is an important observation given the popularity of use of SSRIs. Young patients presenting with central retinal vein occlusions require drug history to be elicited to identify the cause.

CONSENT

As per international standard or university standard, patient's written consent has been collected and preserved by the authors.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Sheehan DV. Current concepts in the treatment of panic disorder. *J Clin Psychiatry*. 1999;60(Suppl 18):16-21.
2. Gorman JM. The use of newer antidepressants for panic disorder. *J Clin Psychiatry*. 1997;58.
3. Cookson J, Duffett R. Fluoxetine: Therapeutic and undesirable effects. *Hosp Med*. 1998;59(8):622-6.
4. Kolar P. Risk factors for central and branch retinal vein occlusion: A meta-analysis of published clinical data. *J Ophthalmol*; 2014.
5. Ashraf M, Souka AA, Singh RP. Central retinal vein occlusion: Modifying current treatment protocols. *Eye (Lond)*. 2016;30(4):505-14.
6. Knox Cartwright NE, Smith P, Tole DM. Branch retinal vein occlusion and fluoxetine. *Ann Ophthalmol*. 2007;39(3):253-4.
7. Hallbäck I, Hägg S, Eriksson AC, Whiss PA. *In vitro* effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation. *Pharmacol Rep*. 2012;64(4):979-83.
8. Warkentin TE, Arnold DM, Nazi I, Kelton JG. The platelet serotonin-release assay. *Am J Hematol*. 2015;90.
9. Omenn GS, Smith LT. A common uptake system for serotonin and dopamine in human platelets. *J Clin Invest*. 1978;62(2):235-40
10. Carneiro AM, Blakely RD. Serotonin-, protein kinase C- and Hic-5-associated redistribution of the platelet serotonin transporter. *J Biol Chem*. 2006;281(34):24769-80.

© 2017 Agraharam et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<http://sciencedomain.org/review-history/20230>